New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
09:57 EDTARIAARIAD spikes higher following Daily Mail report Eli Lilly approached
Eli Lilly (LLY) was reported earlier by the Daily Mail to be a potential suitor for the company, saying it had approached ARIAD (ARIA) with a possible deal. It was reported that Lilly might be willing to pay up to $20 per share. At the current price of $7.25, the stock is up over 8%. Resistance is at the session high at $7.48, while support is at the session low at $7.12.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:37 EDTARIAARIAD announces CHMP adopts final opinion on Iclusig
ARIAD Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events. The company said, "We are now well positioned to complete pricing and reimbursement negotiations in Europe and to ensure that Iclusig is available to appropriate Philadelphia-chromosome positive leukaemia patients."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use